Carcinoembryonic antigen, ferritin, anionic glycoproteins, and their sialic acid content in advanced colorectal cancer.

The efficiency of the combination of four tumor markers in recognizing advanced (recurrent or metastatic) colorectal cancer was evaluated. In 31 normal volunteers and in 31 patients with histologically documented colorectal tumor, we measured serum levels of carcinoembryonic antigen (CEA), ferritin, anionic glycoproteins, and their sialic acid content (SA). CEA, ferritin, anionic glycoproteins and SA mean levels were significantly higher in patients than in normal subjects. Among the four markers CEA was the most sensitive (87.1%) and SA the most specific (100%). By using CEA and SA in combination in 29 out of 31 patients, either marker was abnormally high. Ferritin and anionic glycoproteins did not render additional information. CEA serum levels were elevated in 14 out of 15 patients with liver metastasis, while SA was elevated in six out of 15. CEA maintains its central cole as tumor marker in colorectal cancer; the combined use of CEA and SA may add to precision in detecting patients with advanced colorectal cancer. Anionic glycoproteins and ferritin seem of limited usefulness.

[Significance of certain neoplastic markers in a series of patients with lung cancer]. / Significato di alcuni marcatori di neoplasia in una casistica di pazienti affetti da carcinoma polmonare.

Perchloric acid soluble proteins (PPS) and their content of N-acetylneuraminic acid (NANA) may serve as valuable tumor markers for a variety of malignant neoplasms. To evaluate their clinical significance, PPS, NANA and carcino-embryonic antigen (CEA) were measured in 32 patients with lung cancer. High PPS (greater than or equal to 0,73 mg/ml) and NANA (greater than or equal to 96 micrograms/ml) levels occurred in 8 of 50 (16%) healthy volunteers and respectively in 22% and 54% of patients. CEA levels were high (greater than or equal to 3 ng/ml) in 1 out of 21 (5%) healthy volunteers and in 83% of the patients; 84% of the patients showed an elevation of NANA and of CEA. The highest values of the three markers seem to be associated with extensive disease but no statistically significant difference has emerged from the comparison of patients with limited disease with the ones with extensive involvement. Changes of the tumor mass correlate with changes of serum levels of PPS, NANA and CEA. It is concluded that CEA determination is clinically valuable in lung cancer, while PPS and NANA do not provide greater information.

Anionic glycoproteins and their hexosamine content in neoplastic patients: relationships with the clinical stage and the course of the disease.

In 40 healthy subjects, in 47 non-cancer patients, and in 142 cancer patients, perchloric acid soluble glycoproteins (PASG) and hexosamines were determined to investigate their tumor specificity and correlation with the tumor mass. Cancer patients were divided into three subgroups: CI, no evidence of cancer (after radical surgery); CII, locoregional disease; CIII, widespread metastatic disease. There was no statistically significant difference in PASG among normals, non-cancer and CI patients; hexosamines in non-cancer and in CI patients were higher (P less than 0.002) than in normals; both PASG and hexosamines were significantly higher in CII and CIII patients than in normals (P less than 0.001). In the CI group, 62% of patients who relapsed within 10 months after surgery had high hexosamine values, whereas 69% of patients who did not relapse showed normal levels (P less than 0.05). PASG and hexosamines significantly increased with cancer progression and decreased when objective response to treatment was achieved. They are not tumor specific, but seem to be related to the tumor burden; hexosamines seem to have some prognostic value.

Rheumatoid knee synovitis successfully treated with intra-articular rifamycin SV.

Thirty rheumatoid patients with persistent knee effusion were treated intra-articularly with rifamycin SV, 500 mg weekly, or with saline solution, 10 ml, in a double-blind study. A complete disappearance of effusion and an impressive clinical improvement was observed in the patients on rifamycin. The synovial fluid and membrane underwent some changes. In 2 patients the rifamycin caused a painful local reaction. After a follow-up of 5 years only one patient has experienced effusion relapse, 5 months after the termination of rifamycin SV treatment. The patients on saline showed no significant change. On the basis of the results obtained from the monoarthritis experimental model and from clinical trials it is tempting to consider that rifamycin has an antimitotic effect, impeding the synthesis of RNA and DNA polymerases in immunocompetent cells.